memantine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
adamantane derivatives 1679 19982-08-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • memantine
  • alzantin
  • memantina
  • memantine hydrochloride
  • ebixa
  • namenda
  • maruxa
  • memantine HCl
  • nemdatine
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
  • Molecular weight: 179.31
  • Formula: C12H21N
  • CLOGP: 3.03
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -3.60
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.32 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 48 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2003 FDA FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 313.02 14.21 531 19723 328566 46337242
Confusional state 299.31 14.21 357 19897 159535 46506273
Agitation 227.50 14.21 190 20064 55225 46610583
Dementia 199.81 14.21 107 20147 14823 46650985
Abnormal behaviour 195.90 14.21 119 20135 20939 46644869
Aggression 187.46 14.21 119 20135 22625 46643183
Hallucination 182.02 14.21 160 20094 49791 46616017
Somnolence 127.86 14.21 237 20017 156284 46509524
Psychomotor hyperactivity 93.69 14.21 56 20198 9557 46656251
Dementia Alzheimer's type 92.28 14.21 30 20224 1165 46664643
Delirium 91.42 14.21 96 20158 37132 46628676
Product administration interrupted 88.80 14.21 23 20231 391 46665417
Bradycardia 87.65 14.21 125 20129 66173 46599635
Rheumatoid arthritis 87.42 14.21 4 20250 240211 46425597
Hallucination, visual 83.17 14.21 66 20188 17807 46648001
Disorientation 78.07 14.21 88 20166 36830 46628978
Myoclonus 77.73 14.21 58 20196 14294 46651514
Loss of consciousness 74.96 14.21 153 20101 108085 46557723
Seizure 69.29 14.21 160 20094 122894 46542914
Drug hypersensitivity 57.90 14.21 17 20237 243808 46422000
Body tinea 54.50 14.21 19 20235 916 46664892
Orthostatic hypotension 54.22 14.21 60 20194 24598 46641210
Drug interaction 54.03 14.21 202 20052 202892 46462916
Dyskinesia 52.89 14.21 64 20190 28861 46636947
Cognitive disorder 52.37 14.21 72 20182 36811 46628997
Syncope 52.22 14.21 130 20124 104673 46561135
Speech disorder 51.95 14.21 71 20183 36096 46629712
Delusion 51.37 14.21 41 20213 11147 46654661
Urinary tract infection 50.44 14.21 209 20045 220057 46445751
Cerebral atrophy 49.96 14.21 29 20225 4687 46661121
Incoherent 48.47 14.21 28 20226 4484 46661324
Altered state of consciousness 46.55 14.21 54 20200 23294 46642514
Dysphagia 46.22 14.21 103 20151 77209 46588599
Sedation 44.03 14.21 52 20202 22858 46642950
Aphasia 43.96 14.21 58 20196 28509 46637299
Chorea 43.64 14.21 17 20237 1123 46664685
Infection susceptibility increased 41.99 14.21 20 20234 2159 46663649
Hypernatraemia 41.83 14.21 29 20225 6372 46659436
Urinary retention 41.79 14.21 54 20200 26007 46639801
Electrocardiogram PR prolongation 40.77 14.21 14 20240 645 46665163
Gait disturbance 39.85 14.21 146 20108 145117 46520691
Arthralgia 38.34 14.21 62 20192 364541 46301267
Epilepsy 37.77 14.21 49 20205 23689 46642119
Inhibitory drug interaction 37.50 14.21 18 20236 1977 46663831
Alopecia 35.57 14.21 13 20241 162401 46503407
Dyspnoea 35.21 14.21 111 20143 515437 46150371
Sinusitis 34.77 14.21 7 20247 129761 46536047
Lack of spontaneous speech 34.58 14.21 9 20245 156 46665652
Impaired quality of life 34.51 14.21 20 20234 3222 46662586
Pain 34.49 14.21 100 20154 476848 46188960
Joint swelling 33.59 14.21 15 20239 166058 46499750
Mental status changes 32.66 14.21 59 20195 38029 46627779
Pain in extremity 32.14 14.21 39 20215 258641 46407167
Restlessness 32.05 14.21 47 20207 25477 46640331
Hypersomnia 31.26 14.21 36 20218 15403 46650405
Depressed level of consciousness 30.26 14.21 65 20189 47504 46618304
Akinesia 30.11 14.21 15 20239 1786 46664022
Apathy 29.93 14.21 25 20229 7243 46658565
Hyponatraemia 29.60 14.21 104 20150 101228 46564580
Gait inability 29.51 14.21 54 20200 35149 46630659
Glucose tolerance impaired 29.50 14.21 21 20233 4810 46660998
Diet refusal 29.28 14.21 11 20243 658 46665150
Lethargy 29.26 14.21 67 20187 51104 46614704
Subdural haematoma 29.21 14.21 32 20222 12965 46652843
Product adhesion issue 29.02 14.21 21 20233 4934 46660874
Balance disorder 28.97 14.21 77 20177 64444 46601364
Behaviour disorder 28.90 14.21 15 20239 1946 46663862
Tremor 28.21 14.21 112 20142 115527 46550281
Infusion related reaction 28.08 14.21 5 20249 101203 46564605
Immobile 28.08 14.21 20 20234 4586 46661222
Hip fracture 27.86 14.21 45 20209 26511 46639297
Memory impairment 27.63 14.21 85 20169 77252 46588556
Extrapyramidal disorder 27.54 14.21 29 20225 11239 46654569
Posture abnormal 27.34 14.21 15 20239 2175 46663633
Dehydration 27.26 14.21 139 20115 159401 46506407
Swelling 27.20 14.21 10 20244 124501 46541307
Electrocardiogram QT prolonged 26.95 14.21 65 20189 51260 46614548
Accidental overdose 26.73 14.21 38 20216 20028 46645780
Medication error 26.65 14.21 48 20206 30863 46634945
Belligerence 25.54 14.21 7 20247 149 46665659
Headache 25.45 14.21 114 20140 478238 46187570
Emotional poverty 25.32 14.21 8 20246 283 46665525
Blood creatine phosphokinase increased 25.12 14.21 44 20210 27680 46638128
Purpura 25.00 14.21 26 20228 9932 46655876
Dizziness 24.43 14.21 240 20014 340174 46325634
Device pacing issue 24.15 14.21 5 20249 29 46665779
Rash 24.11 14.21 77 20177 356435 46309373
Nausea 23.79 14.21 188 20066 687266 45978542
Pneumonia aspiration 23.42 14.21 46 20208 31559 46634249
Pleurothotonus 23.39 14.21 11 20243 1154 46664654
Decreased appetite 23.39 14.21 154 20100 193682 46472126
Encephalopathy 22.64 14.21 47 20207 33542 46632266
Hypophagia 22.13 14.21 43 20211 29263 46636545
Nasopharyngitis 21.56 14.21 21 20233 153977 46511831
Akathisia 20.92 14.21 21 20233 7693 46658115
Head injury 20.91 14.21 38 20216 24598 46641210
Back pain 20.85 14.21 37 20217 210002 46455806
Inappropriate antidiuretic hormone secretion 20.72 14.21 28 20226 14074 46651734
Accidental exposure to product by child 20.71 14.21 10 20244 1113 46664695
Drug-device interaction 20.41 14.21 5 20249 67 46665741
Asthenia 20.24 14.21 215 20039 310860 46354948
Screaming 19.78 14.21 14 20240 3177 46662631
Crying 19.74 14.21 34 20220 21107 46644701
Failure to thrive 19.67 14.21 19 20235 6645 46659163
Treatment failure 19.46 14.21 8 20246 93079 46572729
Wrong patient received product 19.25 14.21 11 20243 1726 46664082
Cough 19.08 14.21 45 20209 230204 46435604
Impaired self-care 19.06 14.21 11 20243 1757 46664051
Abdominal pain 19.03 14.21 45 20209 229986 46435822
Intestinal pseudo-obstruction 18.85 14.21 8 20246 659 46665149
Disturbance in attention 18.79 14.21 42 20212 31518 46634290
Condition aggravated 18.65 14.21 175 20079 244877 46420931
Diabetic hyperosmolar coma 18.25 14.21 7 20247 443 46665365
Pulmonary embolism 18.10 14.21 94 20160 108491 46557317
Parkinson's disease 17.74 14.21 10 20244 1529 46664279
Floppy iris syndrome 17.48 14.21 5 20249 125 46665683
Pyrexia 17.41 14.21 85 20169 348717 46317091
Asthma 17.38 14.21 9 20245 91533 46574275
Neutropenia 17.33 14.21 22 20232 143182 46522626
Drug ineffective 17.19 14.21 200 20054 677638 45988170
Generalised tonic-clonic seizure 17.17 14.21 37 20217 27085 46638723
Cerebral haemorrhage 17.16 14.21 38 20216 28333 46637475
Unresponsive to stimuli 17.15 14.21 41 20213 32133 46633675
Pancreatitis acute 16.99 14.21 35 20219 24837 46640971
Death 16.98 14.21 221 20033 335327 46330481
Parkinsonism 16.88 14.21 19 20235 7929 46657879
Arthropathy 16.57 14.21 8 20246 84692 46581116
Stupor 16.37 14.21 13 20241 3507 46662301
International normalised ratio increased 16.25 14.21 51 20203 46832 46618976
Completed suicide 16.07 14.21 24 20230 145896 46519912
Hypoglycaemia 16.05 14.21 56 20198 54293 46611515
Granulocytopenia 15.50 14.21 15 20239 5258 46660550
Hypersensitivity 15.34 14.21 26 20228 150295 46515513
Bone density decreased 15.30 14.21 20 20234 9732 46656076
General physical health deterioration 15.19 14.21 94 20160 115675 46550133
Mania 15.12 14.21 21 20233 10825 46654983
Bradykinesia 15.01 14.21 13 20241 3953 46661855
Muscle rigidity 14.97 14.21 20 20234 9941 46655867
Urinary incontinence 14.83 14.21 36 20218 28494 46637314
Non-24-hour sleep-wake disorder 14.70 14.21 3 20251 16 46665792
Systemic lupus erythematosus 14.63 14.21 5 20249 65175 46600633
Injection site erythema 14.60 14.21 7 20247 74420 46591388
Oropharyngeal pain 14.52 14.21 7 20247 74161 46591647
Neuropathy peripheral 14.41 14.21 11 20243 90882 46574926
Marasmus 14.39 14.21 6 20248 473 46665335

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 265.44 15.38 208 14516 48851 29888903
Confusional state 215.04 15.38 296 14428 134538 29803216
Fall 200.34 15.38 336 14388 181536 29756218
Dementia 194.14 15.38 103 14621 12358 29925396
Aggression 156.57 15.38 136 14588 36771 29900983
Abnormal behaviour 130.55 15.38 105 14619 25518 29912236
Agitation 128.06 15.38 145 14579 53928 29883826
Somnolence 111.76 15.38 183 14541 96580 29841174
Product administration interrupted 107.79 15.38 21 14703 72 29937682
Pleurothotonus 101.44 15.38 32 14692 991 29936763
Gait disturbance 88.41 15.38 143 14581 74634 29863120
Delusion 78.33 15.38 57 14667 11932 29925822
Delirium 70.21 15.38 93 14631 40538 29897216
Dementia Alzheimer's type 61.38 15.38 18 14706 433 29937321
Eosinophilic pleural effusion 44.20 15.38 12 14712 216 29937538
Memory impairment 43.73 15.38 71 14653 37103 29900651
Sopor 43.53 15.38 39 14685 10952 29926802
Condition aggravated 41.26 15.38 155 14569 137711 29800043
Product adhesion issue 40.67 15.38 18 14706 1447 29936307
Balance disorder 40.64 15.38 68 14656 36425 29901329
Depressed level of consciousness 39.63 15.38 69 14655 38153 29899601
Hallucination, visual 39.41 15.38 44 14680 16069 29921685
Cognitive disorder 39.02 15.38 53 14671 23637 29914117
Disorientation 38.31 15.38 61 14663 31357 29906397
Spur cell anaemia 36.72 15.38 8 14716 53 29937701
Speech disorder 36.14 15.38 52 14672 24460 29913294
Mental status changes 34.68 15.38 64 14660 37015 29900739
Gait inability 33.87 15.38 44 14680 18797 29918957
Pneumonia aspiration 33.83 15.38 64 14660 37716 29900038
Febrile neutropenia 33.51 15.38 6 14718 106687 29831067
Restlessness 33.40 15.38 48 14676 22551 29915203
Dementia with Lewy bodies 33.17 15.38 12 14712 568 29937186
Bradycardia 32.76 15.38 88 14636 65438 29872316
Prescribed underdose 31.65 15.38 28 14696 7731 29930023
Orthostatic hypotension 31.23 15.38 48 14676 23931 29913823
Foaming at mouth 30.92 15.38 12 14712 691 29937063
Urinary tract infection 30.10 15.38 92 14632 73567 29864187
Death 29.01 15.38 285 14439 356998 29580756
Loss of consciousness 28.66 15.38 95 14629 79280 29858474
Psychomotor hyperactivity 28.33 15.38 27 14697 8197 29929557
Asthenia 27.85 15.38 195 14529 221095 29716659
Subdural haematoma 27.60 15.38 40 14684 18932 29918822
Hyporesponsive to stimuli 27.28 15.38 12 14712 950 29936804
Bradyarrhythmia 27.21 15.38 15 14709 1937 29935817
Myoclonus 26.96 15.38 33 14691 13279 29924475
Tremor 26.14 15.38 89 14635 75274 29862480
Hypersomnia 26.14 15.38 30 14694 11286 29926468
Sedation 26.00 15.38 36 14688 16337 29921417
Sinus bradycardia 25.33 15.38 30 14694 11665 29926089
Parkinsonism 25.30 15.38 24 14700 7245 29930509
Arthralgia 25.24 15.38 18 14706 135773 29801981
Dysphagia 25.23 15.38 73 14651 56625 29881129
Syncope 24.97 15.38 95 14629 84808 29852946
Dyskinesia 24.71 15.38 41 14683 21793 29915961
Hypernatraemia 24.70 15.38 24 14700 7460 29930294
Inappropriate antidiuretic hormone secretion 24.25 15.38 29 14695 11393 29926361
Seizure 24.05 15.38 104 14620 98371 29839383
Urinary incontinence 23.61 15.38 35 14689 16905 29920849
Altered state of consciousness 22.00 15.38 37 14687 19882 29917872
Paranoia 21.85 15.38 26 14698 10162 29927592
Dysstasia 21.21 15.38 26 14698 10479 29927275
Product dose omission issue 21.02 15.38 95 14629 91536 29846218
Nonspecific reaction 20.90 15.38 11 14713 1295 29936459
Pain 20.79 15.38 33 14691 172608 29765146
Completed suicide 20.09 15.38 12 14712 99480 29838274
Conduction disorder 19.28 15.38 12 14712 1939 29935815
Drug hypersensitivity 19.17 15.38 5 14719 68514 29869240
Petit mal epilepsy 18.30 15.38 13 14711 2618 29935136
Therapeutic response unexpected 17.91 15.38 22 14702 8881 29928873
Abnormal dreams 17.88 15.38 21 14703 8094 29929660
Blood sodium increased 17.53 15.38 13 14711 2798 29934956
Application site erythema 17.47 15.38 12 14712 2291 29935463
Incontinence 17.43 15.38 17 14707 5309 29932445
Posture abnormal 17.26 15.38 11 14713 1853 29935901
Illusion 16.81 15.38 8 14716 760 29936994
Accidental poisoning 16.64 15.38 7 14717 497 29937257
Oesophageal dilatation 16.39 15.38 5 14719 138 29937616
Generalised tonic-clonic seizure 16.12 15.38 32 14692 19519 29918235
Respiratory failure 15.45 15.38 16 14708 100626 29837128

Pharmacologic Action:

SourceCodeDescription
ATC N06DA52 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA53 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DX01 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000020015 NMDA Receptor Antagonists
FDA EPC N0000175745 N-methyl-D-aspartate Receptor Antagonist
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35469 thymoanaleptics
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopamine agents
CHEBI has role CHEBI:60643 n-methyl-d-aspartate receptor antagonists
CHEBI has role CHEBI:63726 neuroprotective agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Moderate to Severe Alzheimer's Type Dementia indication
Acute nephropathy contraindication 58574008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate NMDA receptor; GRIN1/GRIN2B Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.26 CHEMBL CHEMBL
Glutamate receptor ionotropic, NMDA 3A Ion channel NEGATIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 9.02 CHEMBL CHEMBL
Glutamate receptor ionotropic, NMDA 1 Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.02 CHEMBL CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C Ion channel Ki 6.15 CHEMBL

External reference:

IDSource
4021409 VUID
N0000148824 NUI
D04905 KEGG_DRUG
41100-52-1 SECONDARY_CAS_RN
4021409 VANDF
C1563959 UMLSCUI
CHEBI:64312 CHEBI
377 PDB_CHEM_ID
CHEMBL1699 ChEMBL_ID
CHEMBL807 ChEMBL_ID
4054 PUBCHEM_CID
D008559 MESH_DESCRIPTOR_UI
DB01043 DRUGBANK_ID
4253 IUPHAR_LIGAND_ID
3952 INN_ID
W8O17SJF3T UNII
236685 RXNORM
169783 MMSL
17635 MMSL
203022 MMSL
47628 MMSL
d04899 MMSL
006597 NDDF
006598 NDDF
406457005 SNOMEDCT_US
406458000 SNOMEDCT_US
426610008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0850 SOLUTION 10 mg ORAL ANDA 32 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 7 mg ORAL NDA 26 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 14 mg ORAL NDA 26 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 21 mg ORAL NDA 26 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 28 mg ORAL NDA 26 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3205 TABLET 5 mg ORAL NDA 28 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3210 TABLET 10 mg ORAL NDA 28 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3407 CAPSULE, EXTENDED RELEASE 7 mg ORAL NDA 28 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3414 CAPSULE, EXTENDED RELEASE 14 mg ORAL NDA 28 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3421 CAPSULE, EXTENDED RELEASE 21 mg ORAL NDA 28 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3428 CAPSULE, EXTENDED RELEASE 28 mg ORAL NDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1221 TABLET 5 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1222 TABLET 10 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1943 SOLUTION 2 mg ORAL ANDA 28 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3870 TABLET 5 mg ORAL NDA 26 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3875 TABLET 10 mg ORAL NDA 26 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8100 TABLET 10 mg ORAL ANDA 27 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8192 TABLET 5 mg ORAL ANDA 27 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8264 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 24 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8319 TABLET 10 mg ORAL ANDA 26 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-1112 TABLET, FILM COATED 5 mg ORAL ANDA 30 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-1113 TABLET, FILM COATED 10 mg ORAL ANDA 30 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6505 TABLET 5 mg ORAL ANDA 26 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6506 TABLET 10 mg ORAL ANDA 26 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6734 CAPSULE, EXTENDED RELEASE 7 mg ORAL ANDA 24 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6735 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 24 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6736 CAPSULE, EXTENDED RELEASE 14 mg ORAL ANDA 24 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6737 CAPSULE, EXTENDED RELEASE 21 mg ORAL ANDA 24 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10370-346 CAPSULE, EXTENDED RELEASE 7 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10370-347 CAPSULE, EXTENDED RELEASE 14 mg ORAL ANDA 28 sections